Los Angeles Capital Management
TBPH

Los Angeles Capital Management’s Theravance Biopharma TBPH Stock Holding History

Los Angeles Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.05M Sell
179,185
-20,404
-10% -$338K 0.01% 507
2026
Q1 		$3.24M Buy
199,589
+25,054
+14% +$443K 0.01% 406
2025
Q4 		$2.5M Sell
174,535
-6,942
-4% -$115K 0.01% 407
2025
Q3 		$2.65M Buy
181,477
+161,627
+814% +$2.04M 0.01% 434
2025
Q2 		$219K Buy
+19,850
New +$193K ﹤0.01% 1163
2024
Q3 		– Sell
-33,760
Closed -$286K – 1296
2024
Q2 		$286K Buy
+33,760
New +$305K ﹤0.01% 1029

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Los Angeles Capital Management's TBPH Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Theravance Biopharma (TBPH) stake by 10% in Q2 2026, selling an estimated $338K and leaving 179,185 shares worth $3.05M. The position accounts for 0.01% of the portfolio, ranked #507.

Los Angeles Capital Management first reported a position in TBPH in Q2 2024 and has held it in 6 quarters since. The position peaked at $3.24M in Q1 2026. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Los Angeles Capital Management held 179,185 shares of Theravance Biopharma worth $3.05M as of Q2 2026.
  • Los Angeles Capital Management sold 20,404 Theravance Biopharma shares in Q2 2026, an estimated $338K.
  • Theravance Biopharma made up 0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #507 holding.
  • Los Angeles Capital Management first reported a position in Theravance Biopharma in Q2 2024 and has held it in 6 quarters since.
  • Los Angeles Capital Management's Theravance Biopharma position peaked at $3.24M in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.